期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 115, 期 9, 页码 2572-2583出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI24762
关键词
-
资金
- NHLBI NIH HHS [P01 HL068744, HL68744] Funding Source: Medline
- NIAID NIH HHS [R01 AI050953, AI42284, AI50953, AI43407, R01 AI043407-09, R01 AI043407, R21 AI042284, R01 AI042284] Funding Source: Medline
- NINDS NIH HHS [R01 NS044044, NS44044] Funding Source: Medline
Natural killer T (NKT) cells recognize glycolipid antigens presented by the MHC class I-related glycoprotein CD1d. The in vivo dynamics of the NKT cell population in response to glycolipid activation remain poorly understood. Here, we show that a single administration of the synthetic glycolipid a-galactosylceramide (a-GalCer) induces long-term NKT cell unresponsiveness in mice. NKT cells failed to proliferate and produce IFN-gamma upon alpha-GalCer restimulation but retained the capacity to produce IL-4. Consequently, we found that activation of anergic NKT cells with alpha-GalCer exacerbated, rather than prevented, B16 metastasis formation, but that these cells retained their capacity to protect mice against experimental autoimmune encephalomyelitis. NKT cell anergy was induced in a thymus-independent manner and maintained in an NKT cell-autonomous manner. The anergic state could be broken by IL-2 and by stimuli that bypass proximal TCR signaling events. Collectively, the kinetics of initial NKT cell activation, expansion, and induction of anergy in response to a-GalCer administration resemble the responses of conventional T cells to strong stimuli such as superantigens. Our findings have important implications for the development of NKT cell-based vaccines and immunotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据